Revvity and BioCorRx Compared in Head-to-Head Analysis

Analysts see more upside potential in Revvity stock compared to BioCorRx.

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Revvity (NYSE:RVTY) and BioCorRx (OTCMKTS:BICX) are both medical companies, but a head-to-head analysis shows Revvity has stronger fundamentals and a more favorable outlook from analysts.

Why it matters

The analysis provides investors with a comparative look at the financial performance, growth prospects, and market positioning of these two healthcare companies, helping inform investment decisions.

The details

Revvity has higher revenue and earnings than BioCorRx, and its stock is trading at a higher price-to-earnings ratio, indicating it is currently the more expensive but potentially more valuable of the two. Revvity also has a stronger consensus rating from analysts, who see more potential upside in the stock compared to BioCorRx. Additionally, Revvity's stock is more volatile, with a beta of 1.1 compared to BioCorRx's beta of 0.33.

  • The analysis was published on March 5, 2026.

The players

Revvity, Inc.

A provider of health sciences solutions, technologies, and services in the Americas, Europe, and Asia.

BioCorRx Inc.

A company that develops and provides treatment programs for substance abuse and related disorders in the United States.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the relative strengths and weaknesses of Revvity and BioCorRx, providing investors with valuable insights to consider when evaluating these two healthcare companies as potential investment opportunities.